364 related articles for article (PubMed ID: 27286189)
81. Biological evaluation of a novel doxorubicin-peptide conjugate for targeted delivery to EGF receptor-overexpressing tumor cells.
Ai S; Duan J; Liu X; Bock S; Tian Y; Huang Z
Mol Pharm; 2011 Apr; 8(2):375-86. PubMed ID: 21241067
[TBL] [Abstract][Full Text] [Related]
82. Hyaluronic acid derivative-based self-assembled nanoparticles for the treatment of melanoma.
Jin YJ; Termsarasab U; Ko SH; Shim JS; Chong S; Chung SJ; Shim CK; Cho HJ; Kim DD
Pharm Res; 2012 Dec; 29(12):3443-54. PubMed ID: 22886625
[TBL] [Abstract][Full Text] [Related]
83. Cisplatin crosslinked pH-sensitive nanoparticles for efficient delivery of doxorubicin.
Li M; Tang Z; Lv S; Song W; Hong H; Jing X; Zhang Y; Chen X
Biomaterials; 2014 Apr; 35(12):3851-64. PubMed ID: 24495487
[TBL] [Abstract][Full Text] [Related]
84. Smart doxorubicin nanoparticles with high drug payload for enhanced chemotherapy against drug resistance and cancer diagnosis.
Yu C; Zhou M; Zhang X; Wei W; Chen X; Zhang X
Nanoscale; 2015 Mar; 7(13):5683-90. PubMed ID: 25740312
[TBL] [Abstract][Full Text] [Related]
85. Therapeutic Effects of AICAR and DOX Conjugated Multifunctional Nanoparticles in Sensitization and Elimination of Cancer Cells via Survivin Targeting.
Daglioglu C; Okutucu B
Pharm Res; 2017 Jan; 34(1):175-184. PubMed ID: 27783307
[TBL] [Abstract][Full Text] [Related]
86. Amphiphilic polyelectrolyte/prodrug nanoparticles constructed by synergetic electrostatic and hydrophobic interactions with cooperative pH-sensitivity for controlled doxorubicin delivery.
Huang P; Wang W; Zhou J; Zhao F; Zhang Y; Liu J; Liu J; Dong A; Kong D; Zhang J
ACS Appl Mater Interfaces; 2015 Mar; 7(11):6340-50. PubMed ID: 25746122
[TBL] [Abstract][Full Text] [Related]
87. Doxorubicin Delivered Using Nanoparticles Camouflaged with Mesenchymal Stem Cell Membranes to Treat Colon Cancer.
Liu Y; Zhao J; Jiang J; Chen F; Fang X
Int J Nanomedicine; 2020; 15():2873-2884. PubMed ID: 32368059
[TBL] [Abstract][Full Text] [Related]
88. Tumor-targeted and stimulus-responsive polymeric prodrug nanoparticles to enhance the anticancer therapeutic efficacy of doxorubicin.
Kim N; Kwon S; Kwon G; Song N; Jo H; Kim C; Park S; Lee D
J Control Release; 2024 May; 369():351-362. PubMed ID: 38552963
[TBL] [Abstract][Full Text] [Related]
89. Enhanced anti-tumor efficacy and reduced cardiotoxicity of doxorubicin delivered in a novel plant virus nanoparticle.
Alemzadeh E; Dehshahri A; Dehghanian AR; Afsharifar A; Behjatnia AA; Izadpanah K; Ahmadi F
Colloids Surf B Biointerfaces; 2019 Feb; 174():80-86. PubMed ID: 30445253
[TBL] [Abstract][Full Text] [Related]
90. Enhanced Specificity and Drug Delivery in Tumors by cRGD-Anchoring Thermosensitive Liposomes.
Dicheva BM; ten Hagen TL; Seynhaeve AL; Amin M; Eggermont AM; Koning GA
Pharm Res; 2015 Dec; 32(12):3862-76. PubMed ID: 26202516
[TBL] [Abstract][Full Text] [Related]
91. In vitro and in vivo evaluation of antitumor drug-loaded aptamer targeted single-walled carbon nanotubes system.
Zhang H; Hou L; Jiao X; Yandan J; Zhu X; Hongji L; Chen X; Ren J; Xia Y; Zhang Z
Curr Pharm Biotechnol; 2014; 14(13):1105-17. PubMed ID: 24725129
[TBL] [Abstract][Full Text] [Related]
92. Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts.
Zhong Y; Zhang J; Cheng R; Deng C; Meng F; Xie F; Zhong Z
J Control Release; 2015 May; 205():144-54. PubMed ID: 25596560
[TBL] [Abstract][Full Text] [Related]
93. Method of hyperthermia and tumor size influence effectiveness of doxorubicin release from thermosensitive liposomes in experimental tumors.
Willerding L; Limmer S; Hossann M; Zengerle A; Wachholz K; Ten Hagen TL; Koning GA; Sroka R; Lindner LH; Peller M
J Control Release; 2016 Jan; 222():47-55. PubMed ID: 26658073
[TBL] [Abstract][Full Text] [Related]
94. Targeted sialic acid-doxorubicin prodrugs for intracellular delivery and cancer treatment.
Jayant S; Khandare JJ; Wang Y; Singh AP; Vorsa N; Minko T
Pharm Res; 2007 Nov; 24(11):2120-30. PubMed ID: 17668297
[TBL] [Abstract][Full Text] [Related]
95. A multifunctional polymeric nanotheranostic system delivers doxorubicin and imaging agents across the blood-brain barrier targeting brain metastases of breast cancer.
Li J; Cai P; Shalviri A; Henderson JT; He C; Foltz WD; Prasad P; Brodersen PM; Chen Y; DaCosta R; Rauth AM; Wu XY
ACS Nano; 2014 Oct; 8(10):9925-40. PubMed ID: 25307677
[TBL] [Abstract][Full Text] [Related]
96. Optimization of a Stable Linker Involved DEVD Peptide-Doxorubicin Conjugate That Is Activated upon Radiation-Induced Caspase-3-Mediated Apoptosis.
Chung SW; Lee BS; Choi Ju; Kim SW; Kim IS; Kim SY; Byun Y
J Med Chem; 2015 Aug; 58(16):6435-47. PubMed ID: 26263187
[TBL] [Abstract][Full Text] [Related]
97. Structure-directing star-shaped block copolymers: supramolecular vesicles for the delivery of anticancer drugs.
Yang C; Liu SQ; Venkataraman S; Gao SJ; Ke X; Chia XT; Hedrick JL; Yang YY
J Control Release; 2015 Jun; 208():93-105. PubMed ID: 25813888
[TBL] [Abstract][Full Text] [Related]
98. PDEPT: polymer-directed enzyme prodrug therapy. 2. HPMA copolymer-beta-lactamase and HPMA copolymer-C-Dox as a model combination.
Satchi-Fainaro R; Hailu H; Davies JW; Summerford C; Duncan R
Bioconjug Chem; 2003; 14(4):797-804. PubMed ID: 12862433
[TBL] [Abstract][Full Text] [Related]
99. Design and evaluation of a phospholipase D based drug delivery strategy of novel phosphatidyl-prodrug.
Tao X; Jia N; Cheng N; Ren Y; Cao X; Liu M; Wei D; Wang FQ
Biomaterials; 2017 Jul; 131():1-14. PubMed ID: 28365224
[TBL] [Abstract][Full Text] [Related]
100. Chitosan-g-TPGS nanoparticles for anticancer drug delivery and overcoming multidrug resistance.
Guo Y; Chu M; Tan S; Zhao S; Liu H; Otieno BO; Yang X; Xu C; Zhang Z
Mol Pharm; 2014 Jan; 11(1):59-70. PubMed ID: 24229050
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
